Kusajili – Clinical trials directory

Result of your search per sponsor: Innate Pharma S.A

Woman and Man Max 99 years
Innate Pharma S.A Update Il y a 4 ans

A phase I/II open label study of IPH1101 (with low dose of interleukin-2 [IL-2]) in combination with rituximab re-treatment in patients with Follicular Lymphoma The primary objective of this study is to assess the clinical efficacy of IPH1101 (with low-dose IL 2, as aldesleukin), administered in combination with a standard course of rituximab, in patients wit...

Country None
organs None
Specialty None

Closed trial

More information